Axsome Therapeutics (AXSM) Operating Leases (2020 - 2026)

Axsome Therapeutics has disclosed Operating Leases across 6 years of filings, most recently posting $22.4 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $22.4 million, down 6.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.4 million (down 6.36% YoY), and the FY2025 annual result was $23.2 million, up 283.43% from the prior year.
• Operating Leases came in at $22.4 million for Q1 2026 at Axsome Therapeutics, down from $23.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $23.9 million in Q1 2025 to a low of $6.0 million in Q4 2024.
• The 4-year median for Operating Leases is $7.6 million (2023), against an average of $13.7 million.
• Across the five-year window, Operating Leases declined 16.27% in 2024 and soared 283.43% in 2025, its largest moves.
• Axsome Therapeutics' Operating Leases stood at $7.0 million in 2023, then slipped by 14.06% to $6.0 million in 2024, then jumped by 283.43% to $23.2 million in 2025, then dropped by 3.44% to $22.4 million in 2026.
• The last three Operating Leases figures came in at $22.4 million (Q1 2026), $23.2 million (Q4 2025), and $23.0 million (Q3 2025), per Business Quant data.